Biomarker analysis of the phase 3 TORCH trial for first line erlotinib versus chemotherapy in advanced non-small cell lung cancer patients

BACKGROUND: The TORCH phase III trial compared the efficacy of first-line erlotinib followed by chemotherapy at progression (experimental arm) with the reverse sequence (standard arm) in unselected advanced non-small cell lung cancer (NSCLC) patients. Here we report biomarker analyses. METHODS: EGFR...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Lucia, Saieg, Mauro, Di Maio, Massimo, Gallo, Ciro, Butts, Charles, Ciardiello, Fortunato, Feld, Ronald, Cheng, Dengxiao, Gebbia, Vittorio, Burgio, Marco Angelo, Alam, Yasmin, Signoriello, Simona, Rossi, Antonio, Leighl, Natasha, Maione, Paolo, Morabito, Alessandro, Liu, Geoffrey, Tsao, Ming-Sound, Perrone, Francesco, Gridelli, Cesare
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Clinical Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5593664/
https://www.ncbi.nlm.nih.gov/pubmed/28915692
http://dx.doi.org/10.18632/oncotarget.15725

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5593664/
https://www.ncbi.nlm.nih.gov/pubmed/28915692
http://dx.doi.org/10.18632/oncotarget.15725

Ejemplares similares